Iricryn (Bimatoprost)

Bimatoprost binds to FP receptors in the eye, promoting remodeling of the extracellular matrix and increasing uveoscleral outflow of aqueous humor. This enhanced drainage reduces intra‑ocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension.

The dosing regimen for Iricryn is determined by the prescribing ophthalmologist. Typically, a single drop is instilled in the affected eye(s) once daily, but the exact dose and frequency are individualized based on the patient’s condition and response.

Safety of bimatoprost in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Iricryn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Iricryn (bimatoprost) is a prostaglandin analog, a class known for potent intra‑ocular pressure reduction with once‑daily dosing. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, prostaglandin analogs often achieve greater pressure lowering, but individual response and side‑effect profiles vary, so clinicians choose based on patient needs.

Store Iricryn at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from light and moisture, and do not freeze. Discard any eye drops that appear discolored or have been opened beyond the recommended period.

Iricryn is applied as a sterile ophthalmic solution. The patient should wash their hands, tilt the head back, pull down the lower eyelid to form a pocket, and place one drop into the conjunctival sac of the affected eye(s). Close the eye gently and avoid blinking excessively for a few seconds.

Serious but rare risks include uveitis, macular edema, and sudden vision loss. Patients should report any new eye pain, redness, blurred vision, or visual field changes promptly, as these may signal complications requiring immediate medical attention.

Iricryn should not be used by individuals with active ocular inflammation, hypersensitivity to bimatoprost or any component of the formulation, or by those who have experienced severe adverse reactions to prostaglandin analogs. Caution is also advised for patients with a history of uveitis or retinal disease.